SCHEMBL4959166

SCHEMBL4959166

Oc1cccc2cccc(F)c12

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.50
MEN1 O00255 3/20 0.50
KMT2A Q03164 3/20 0.50
DNMT1 P26358 1/20 0.50
CACNA1B Q00975 1/20 0.50
APBA1 Q02410 1/20 0.50
MCL1 Q07820 1/20 0.50
APOBEC3G Q9HC16 1/20 0.50
MAPT P10636 6/20 0.48
HPGD P15428 5/20 0.48
HSD17B10 Q99714 5/20 0.48
TDP1 Q9NUW8 4/20 0.48
THRB P10828 4/20 0.48
ALOX15 P16050 3/20 0.48
RECQL P46063 3/20 0.48
CYP1A2 P05177 3/20 0.48
TSHR P16473 2/20 0.48
SNCA P37840 2/20 0.48
APP P05067 1/20 0.48
CASP1 P29466 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29428517 1.00 ALDH1A1 (0.50) ALDH1A1MEN1KMT2ADNMT1CACNA1B
SCHEMBL29788341 0.81 ALDH1A1 (0.53) ALDH1A1MEN1KMT2AMCL1MAPT
SCHEMBL4112541 0.81 ALDH1A1 (0.53) ALDH1A1MEN1KMT2AMCL1MAPT
SCHEMBL70219 0.81 ALDH1A1 (0.62) ALDH1A1MEN1KMT2ADNMT1CACNA1B
SCHEMBL29363189 0.81 ALDH1A1 (0.62) ALDH1A1MEN1KMT2ADNMT1CACNA1B
SCHEMBL6488214 0.79 MAPT (0.46) ALDH1A1MEN1KMT2ADNMT1CACNA1B
SCHEMBL25181071 0.79 MEN1 (0.56) ALDH1A1MEN1KMT2ADNMT1CACNA1B
SCHEMBL30033048 0.79 ALDH1A1 (0.45) ALDH1A1MEN1KMT2ADNMT1CACNA1B
SCHEMBL12189899 0.79 ALDH1A1 (0.45) ALDH1A1MEN1KMT2ADNMT1CACNA1B
SCHEMBL7126508 0.78 ALDH1A1 (0.59) ALDH1A1MEN1KMT2ADNMT1CACNA1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4216951-B1 KRAS G12D INHIBITORS MIRATI THERAPEUTICS INC (US) 2026-04-01 EP disclosed
US-20230357277-A1 KRAS G12D INHIBITORS ARRAY BIOPHARMA INC. 2023-11-09 US disclosed
US-20230357277-A1 KRAS G12D INHIBITORS ARRAY BIOPHARMA INC. 2023-11-09 US disclosed
US-20230357277-A1 KRAS G12D INHIBITORS ARRAY BIOPHARMA INC. 2023-11-09 US disclosed
US-20180090769-A1 ENERGY DEVICE INCLUDING HALOGENATED CARBON MATERIAL AND METHOD FOR PREPARING THE SAME KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2018-03-29 US disclosed
WO-2015013456-A1 INDICATOR COMPOUNDS, POLYMERIZABLE DERIVATIVES THEREOF AND INFECTION INDICATING MEDICAL DEVICES COMPRISING THE SAME INDICATOR SYSTEMS INTERNATIONAL, INC. (US) 2015-01-29 WO disclosed
EP-1871844-B1 BUBBLE COMPOSITION WITH COLOR CHANGING INDICATOR C2C TECHNOLOGIES LLC (US) 2014-08-27 EP disclosed
EP-1871844-A2 NOVELTY COMPOSITIONS WITH COLOR CHANGING INDICATOR C2C Technologies LLC (US) 2008-01-02 EP disclosed
US-20070010400-A1 Use of color changing indicators in consumer products C2C TECHNOLOGIES, LLC 2007-01-11 US disclosed
US-20060257439-A1 Cleansing compositions with color changing indicator CRAYOLA LLC 2006-11-16 US disclosed
US-20060236470-A1 Novelty compositions with color changing indicator CRAYOLA LLC 2006-10-26 US disclosed
WO-2006105193-A2 PERSONAL CARE COMPOSITIONS WITH COLOR CHANGING INDICATOR C2C TECHNOLOGIES LLC (US) 2006-10-05 WO disclosed
WO-2006105261-A1 CLEANSING COMPOSITIONS WITH COLOR CHANGING INDICATOR C2C TECHNOLOGIES LLC (US) 2006-10-05 WO disclosed
WO-2006105260-A1 ORAL CARE COMPOSITIONS WITH COLOR CHANGING INDICATOR C2C TECHNOLOGIES LLC (US) 2006-10-05 WO disclosed
WO-2006105191-A2 NOVELTY COMPOSITIONS WITH COLOR CHANGING INDICATOR C2C TECHNOLOGIES LLC (US) 2006-10-05 WO disclosed
US-20060222601-A1 Oral care compositions with color changing indicator C2C TECHNOLOGIES, LLC 2006-10-05 US disclosed
US-20060222675-A1 Personal care compositions with color changing indicator C2C TECHNOLOGIES, LLC 2006-10-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060222675-A1 Personal care compositions with color changing indicator CUTA, POLR1C, TYR ALDH1A1 1045/4885MEN1 2817/4885KMT2A 3653/4885
US-20060257439-A1 Cleansing compositions with color changing indicator WASHC5, WASHC4, FHIT ALDH1A1 466/4885MEN1 1113/4885KMT2A 3047/4885
US-20230357277-A1 KRAS G12D INHIBITORS KRAS, NRAS, HRAS ALDH1A1 2681/4885MEN1 465/4885KMT2A 1755/4885
US-20060222601-A1 Oral care compositions with color changing indicator CA9, CA7, TAS2R7 ALDH1A1 1632/4885MEN1 3449/4885KMT2A 2738/4885
US-20070010400-A1 Use of color changing indicators in consumer products NQO2, CA4, CA7 ALDH1A1 67/4885MEN1 3755/4885KMT2A 1465/4885
US-20060236470-A1 Novelty compositions with color changing indicator MITF, CRABP2, SHH ALDH1A1 1689/4885MEN1 3006/4885KMT2A 1508/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.